Analysts See $-0.31 EPS for OncoMed Pharmaceuticals, Inc. (OMED)

February 15, 2018 - By Nellie Frank

 Analysts See $ 0.31 EPS for OncoMed Pharmaceuticals, Inc. (OMED)
Investors sentiment increased to 0.71 in Q3 2017. Its up 0.12, from 0.59 in 2017Q2. It improved, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported.
Wells Fargo Company Mn reported 4,490 shares. Meeder Asset Inc owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 1,346 shares. Manufacturers Life Insur The accumulated 2,762 shares or 0% of the stock. Commercial Bank Of America De reported 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Plante Moran Ltd Com has 380 shares. Schwab Charles Inc has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 50,729 shares. 1,416 are held by Deutsche Commercial Bank Ag. D E Shaw And Com reported 158,016 shares. 13,100 were reported by State Street. Element Cap Mgmt Limited has invested 0.05% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Burt Wealth Advsrs, a Maryland-based fund reported 7,519 shares. Jacobs Levy Equity Mngmt accumulated 0% or 41,800 shares. Vanguard Gru holds 0% or 1.03M shares. Connor Clark And Lunn Invest accumulated 0% or 69,900 shares. First Eagle Invest Mngmt Limited Liability Com stated it has 219,420 shares.

Since October 10, 2017, it had 0 buys, and 5 sales for $27,111 activity. Gurney Austin sold $5,295 worth of stock or 1,248 shares. Lewicki John A. also sold $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, October 10. Patel Sunil sold $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, October 10. 1,398 shares were sold by HASTINGS PAUL J, worth $5,931.

Analysts expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report $-0.31 EPS on March, 14.They anticipate $0.39 EPS change or 55.71 % from last quarter’s $-0.7 EPS. After having $-0.28 EPS previously, OncoMed Pharmaceuticals, Inc.’s analysts see 10.71 % EPS growth. The stock decreased 1.45% or $0.03 during the last trading session, reaching $2.04. About 57,814 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since February 15, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Ratings Coverage

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. Mizuho maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Wednesday, January 6. Mizuho has “Neutral” rating and $40 target. The company was initiated on Monday, April 18 by Cantor Fitzgerald. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. Jefferies maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Wednesday, August 10 with “Buy” rating. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Hold” rating given on Friday, October 6 by SunTrust. The firm earned “Outperform” rating on Tuesday, April 12 by BMO Capital Markets. As per Tuesday, April 11, the company rating was downgraded by BMO Capital Markets. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. Jefferies maintained the stock with “Buy” rating in Thursday, August 24 report. Mizuho maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Tuesday, January 26. Mizuho has “Buy” rating and $15 target.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $77.23 million. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: which released: “OncoMed Pharmaceuticals’ (OMED) CEO Paul Hastings on Q2 2017 Results …” on August 03, 2017, also with their article: “Is OncoMed A Contrarian Buy?” published on May 25, 2017, published: “OncoMed Pharmaceuticals: Is This $4.50 Busted IPO A Buy?” on September 29, 2017. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: and their article: “Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed …” published on January 08, 2018 as well as‘s news article titled: “OncoMed Pharmaceuticals to Report Second Quarter Financial Results on August …” with publication date: July 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.